Genetically Predicted Type 2 Diabetes Mellitus Liability, Glycated Hemoglobin and Cardiovascular Diseases: A Wide-Angled Mendelian Randomization Study
Mason, Amy M.
Di Angelantonio, Emanuele
MetadataShow full item record
Liu, B., Mason, A. M., Sun, L., Di Angelantonio, E., Gill, D., & Burgess, S. (2021). Genetically Predicted Type 2 Diabetes Mellitus Liability, Glycated Hemoglobin and Cardiovascular Diseases: A Wide-Angled Mendelian Randomization Study. [Other]. https://doi.org/10.3390/genes12101644
(1) Aim: To investigate the causal effects of T2DM liability and glycated haemoglobin (HbA1c) levels on various cardiovascular disease outcomes, both in the general population and in non-diabetic individuals specifically. (2) Methods: We selected 243 variants as genetic instruments for T2DM liability and 536 variants for HbA1c. Linear Mendelian randomization analyses were performed to estimate the associations of genetically-predicted T2DM liability and HbA1c with 12 cardiovascular disease outcomes in 367,703 unrelated UK Biobank participants of European ancestries. We performed secondary analyses in participants without diabetes (HbA1c 6.5% with no diagnosed diabetes), and in participants without diabetes or pre-diabetes (HbA1c 5.7% with no diagnosed diabetes). (3) Results: Genetically-predicted T2DM liability was positively associated (p 0.004, 0.05/12) with peripheral vascular disease, aortic valve stenosis, coronary artery disease, heart failure, ischaemic stroke, and any stroke. Genetically-predicted HbA1c was positively associated with coronary artery disease and any stroke. Mendelian randomization estimates generally shifted towards the null when excluding diabetic and pre-diabetic participants from analyses. (4) Conclusions: This genetic evidence supports causal effects of T2DM liability and HbA1c on a range of cardiovascular diseases, suggesting that improving glycaemic control could reduce cardiovascular risk in a general population, with greatest benefit in individuals with diabetes.
mendelian randomization, type 2 diabetes mellitus, hemoglobin A1c, average blood glucose, cardiovascular diseases
Wellcome Trust and the Royal Society (204623/Z/16/Z, RE/18/4/34215, CL-2020-16-001)
External DOI: https://doi.org/10.3390/genes12101644
This record's DOI: https://doi.org/10.17863/CAM.77144
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: email@example.com